Evidence map›Paper›PMID 41022704›Full record

ArticleSignal transduction and targeted therapy2025

Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance.

Claire M Storey, Mohamed Altai, Katharina Lückerath, Wahed Zedan, Henan Zhu, Lara Breuer, Marija Trajkovic-Arsic, Julie Park, Abbie Hasson, Jens Siveke and 21 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Signal transduction and targeted therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Key regulatory elements of the TGFβ-LRRC15 axis predict disease progression and immunotherapy resistance across cancer types.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

31 authors.

Claire M Storey *Department of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0003-0792-1569
Mohamed Altai *Division of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Katharina LückerathDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, DKTK, Essen, Germany.
Wahed ZedanDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Henan ZhuDepartment of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Lara BreuerDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, DKTK, Essen, Germany.
Marija Trajkovic-ArsicBridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.
Julie ParkDepartment of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Abbie HassonDepartment of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Jens SivekeBridge Institute of Experimental Tumor Therapy (BIT) and Division of Solid Tumor Translational Oncology (DKTK), West German Cancer Center, University Hospital Essen, University of Duisburg-Essen, Essen, Germany.ORCID 0000-0002-8772-4778
Diane AbouDepartment of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
Haley MarksAdvanced Light Microscopy and Spectroscopy Laboratory, California Nanosystems Institute, UCLA, Los Angeles, CA, USA.
Enna UlmertDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Alexander RidleyDepartment of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Marcella SafiDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Urpo LamminmäkiDepartment of Life Technologies, University of Turku, Turku, Finland.
Constance YuenCalifornia NanoSystems Institute, UCLA, Los Angeles, CA, USA.
Susanne GeresDivision of Oncology and Pathology, Department of Clinical Sciences, Lund University, Lund, Sweden.
Liqun MaoDepartment of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0001-9704-3995
Michael ChengBioinformatics Interdepartmental Program, University of California, Los Angeles, CA, USA.
Sumit K SubudhiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Bilal A SiddiquiDepartment of Genitourinary Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Noah FedermanPediatric Bone and Soft Tissue Sarcoma Program at UCLA, Los Angeles, CA, USA.
Johannes CzerninAhmanson Translational Theranostics Division, Department of Molecular and Medical Pharmacology, UCLA, Los Angeles, CA, USA.
Ken HerrmannDepartment of Nuclear Medicine, University Hospital Essen, University of Duisburg-Essen, DKTK, Essen, Germany.
Laurent BentolilaAdvanced Light Microscopy and Spectroscopy Laboratory, California Nanosystems Institute, UCLA, Los Angeles, CA, USA.
Xia YangDepartment of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0002-3971-038X
Thomas G GraeberDepartment of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.ORCID 0000-0001-8574-9181
Robert DamoiseauxDepartment of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA.
Daniel ThorekDepartment of Radiology, Washington University School of Medicine, St. Louis, MO, USA.
David UlmertDepartment of Molecular & Medical Pharmacology, University of California Los Angeles (UCLA), Los Angeles, CA, USA. hulmert@mednet.ucla.edu.

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI SELWYN M VICKERS · 1985 to 2026
$347.4M
Women's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Robert Damoiseaux · 1985 to 2026
$134.5M
UCLA SPORE IN PROSTATE CANCERP50CA092131 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI REITER, ROBERT E · 2002 to 2023
$42.6M
Virology CoreP30AI028697 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ZACK, JEROME A. · 1991 to 2018
$39.9M
UCLA SPORE in Brain CancerP50CA211015 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Yvonne Yu-Hsuan Chen · 2017 to 2026
$25.2M
Genetic Predictors of Prostate Cancer SurvivalR01CA244948 · NCI · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ROBERT J. KLEIN · 2021 to 2026
$4.1M
The Radium-223 Combination Therapy Space; Improving Response and Clarifying ToxicitiesR01CA240711 · NCI · WASHINGTON UNIVERSITY · PI MICHALSKI, JEFF M., THOREK, DANIEL LYNDON JAFFE · 2020 to 2024
$2.2M
Influence of intra-individual variability in serial screening samples on clinical decision-making for risk stratification and biopsy by a single PSA and additional markersU01CA266535 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI JAMES A EASTHAM · 2022 to 2026
$2.0M
Opening the Therapeutic Window for PSMA-Targeted Molecular RadiotherapyR01CA229893 · NCI · WASHINGTON UNIVERSITY · PI THOREK, DANIEL LYNDON JAFFE · 2019 to 2024
$1.9M
Kallikrein-Targeted Alpha-Particle Therapy of Late-Stage Prostate CancerR01CA201035 · NCI · WASHINGTON UNIVERSITY · PI THOREK, DANIEL LYNDON JAFFE · 2017 to 2020
$1.4M
Multiphoton Microscope for Deep Tissue ImagingS10OD025017 · OD · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI BENTOLILA, LAURENT A. · 2018 to 2018
$599k
NCI NIH HHS P30 CA008748NCI NIH HHS P30 CA016042NCI NIH HHS P50 CA092131NCI NIH HHS P50 CA211015NCI NIH HHS R01 CA201035NCI NIH HHS R01 CA229893NCI NIH HHS R01 CA240711NCI NIH HHS R01 CA244948NCI NIH HHS U01 CA266535NIAID NIH HHS P30 AI028697NIH HHS S10 OD025017
6 · The paper itself

Abstract

Leucine-rich repeat containing 15 (LRRC15) has emerged as an attractive biomarker and target for cancer therapy. Transforming growth factor-β (TGFβ) induces the expression of this plasma membrane protein specifically in aggressive and treatment resistant tumor cells derived from mesenchymal stem cells, with minimal expression observed in non-neoplastic tissues. We have developed a humanized monoclonal antibody, DUNP19, that specifically binds with high affinity to a phylogenetically conserved LRRC15 epitope and is rapidly internalized upon LRRC15 binding. In multiple subcutaneous and orthotopic tumor xenograft mouse models, Lutetium-177 labeled DUNP19 ([

Indexed as

Antibodies, Monoclonal, HumanizedImmunotherapyMembrane ProteinsNeoplasm ProteinsNeoplasmsAnimalsCell Line, TumorDrug Resistance, NeoplasmHumansLutetiumMiceRadioisotopesTransforming Growth Factor betaXenograft Model Antitumor AssaysAntibodies, Monoclonal, HumanizedLutetiumLutetium-177Membrane ProteinsNeoplasm ProteinsRadioisotopesTransforming Growth Factor beta

Identifiers

PMID41022704
PMCPMC12480655

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.